ArticleNature2024
Forget lung, breast or prostate cancer: why tumour naming needs to change.
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacy.Cancer immunology, immunotherapy : CII · 2025Pooled it
- Next-Generation Sequencing-Based Molecular Profiling and Management of Advanced Solid Tumors: A Real-World Experience in a Community-Based Academic Cancer Center.Cancer medicine · 2026Article
- Personalized medicine, scientific revolution or self-serving illusion: viewpoint from EORTC-PAMM Group.ESMO open · 2026Review
- When genomics and histopathology diverge: insights from pathologic review of genomic-directed specimens.Virchows Archiv : an international journal of pathology · 2026Article
- A unified therapeutic theory for treating cancer via master regulators of the universal apoptosis network.Cell death discovery · 2026Review
- Sorting out and navigating uncertainty in precision medicine.History and philosophy of the life sciences · 2026Article
- Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Observational
- Integration of omics data in the diagnosis and therapy of glioblastoma.Brain pathology (Zurich, Switzerland) · 2026Review
- Systematic pan-cancer analysis reveals context-dependent prognostic and immunological roles of WDR1 with divergent effects in renal and gastric cancers.Frontiers in immunology · 2026Article
- Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma.Frontiers in oncology · 2026Article
- Novae: a graph-based foundation model for spatial transcriptomics data.Nature methods · 2025Article
- Cancer treatment paradigms in the precision medicine era.Nature medicine · 2025Article
- Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment.Nature reviews. Clinical oncology · 2025Review
- Cancer of unknown primary: the hunt for its elusive tissue-of-origin - is it time to call off the search?British journal of cancer · 2025Review
- Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Molecular oncology · 2025Review
- Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care.JCO precision oncology · 2025Article
- Integrative single-cell transcriptomic analysis deciphers heterogeneous characteristics of gastrointestinal tract cancer.Clinical and translational medicine · 2025Article
- Large language models-enabled digital twins for precision medicine in rare gynecological tumors.NPJ digital medicine · 2025Article
- Organelle-oriented nanomedicines in tumor therapy: Targeting, escaping, or collaborating?Bioactive materials · 2025Review
- Pan-cancer analysis shapes the understanding of cancer biology and medicine.Cancer communications (London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
38347121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.